EntreMed Inc. of Rockville, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, said it narrowed its loss for the second quarter.
EntreMed reported a net loss of $1.7 million, or 17 cents per share, for this year’s quarter versus a net loss of $4.9 million, or 57 cents per share, for the same period last year. The company grossed nearly $9,000 in revenue versus no revenue in the prior-year period.
EntreMed said it was able to cut its loss by spending less for research and development and general and administrative expenses. There were no analysts’ estimates issued for EntreMed during the quarter.